LXO IRELAND
SpecialtyLXO IRELAND is a specialty pharmaceutical company with 3 FDA-approved products.
LXO IRELAND's Key Drugs
LXO IRELAND's core commercial portfolio centers on BARHEMSYS, GOPRELTO — its most strategically important drugs approved in the last 15 years.
LXO IRELAND's Recent FDA Approvals
New NDA/BLA approvals for LXO IRELAND over the last two years — novel drugs only, excluding generics and label supplements.
LXO IRELAND's Therapeutic Areas
Disease areas where LXO IRELAND has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LXO IRELAND Pipeline Snapshot
Active clinical trials for LXO IRELAND across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BARHEMSYS leads revenue
- • 2 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling